Liliya Rinatovna Khusnutdinova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Liliya Rinatovna Khusnutdinova has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Dinara Il'GIzarovna Sadykova
Kazan State Medical University
4 shared publications - Razina Ramazanovna Nigmatullina
Kazan State Medical University
3 shared publications - Tamara P. Makarova
Kazan State Medical University; Children’s Republican Clinical Hospital
3 shared publications - Evgeniya Sergeevna Slastnikova
Children’s Republican Clinical Hospital; Kazan State Medical University
2 shared publications - A. I. Ziatdinov
Children’s Republican Clinical Hospital
1 shared publication - Anna A. Kucheryavaya
Children’s Republican Clinical Hospital
1 shared publication
Latest Publications
- 27 December 2024
- Published by Ulyanovsk State University in Ulyanovsk Medico-biological Journal
- No. 4
ROLE OF DOPAMINE IN THE REGULATION OF CARDIOVASCULAR SYSTEM
Dopamine is an endogenous catecholamine and its effects are not limited to the central nervous system. Thus, dopamine affects the gastrointestinal motility, hormone release, and sodium balance. Recently, the role of peripheral dopamine in regulating cardiac functions has been studied by various scientists. The aim of the review is to summarize the currently available data on the role of dopamine in cardiac regulation. Materials and Methods. Papers from PubMed, Google Scholar, and eLIBRARY.RU were analyzed for the literature review. Results. Dopamine, being an agonist of cardiac α- and β-adrenergic receptors, has positive chronotropic and inotropic cardiac effects. In proximal arteries, catecholamine causes dose-dependent contraction, whereas in distal arteries, low dopamine concentration leads to dilation, while high concentration causes contraction. Due to the wide variety of receptors, dopamine has a cardioprotective effect, reducing cardiac hypertrophy and fibrosis. Experimental studies with laboratory animals have shown that catecholamine suppresses inflammation mediated by NLRP3 inflammasome activation in cardiomyocytes, and reduces IL-6 and endothelin-1 release. Dopamine plays an important role in the pathogenesis of hypertension by regulating epithelial sodium transport and interacting with vasoactive hormones/humoral factors such as aldosterone, angiotensin, renin, and vasopressin. Dopamine may also have a negative cardiac effect. Use of a dopamine-adrenergic receptor agonist increases mortality risk among patients with advanced heart failure. High level of free catecholamine is an independent risk factor for future coronary events in patients with coronary heart disease. Conclusion. Dopamine plays a special role in cardiac regulation. However, further studies are desirable, as it is necessary to examine the changes in the catecholamine concentration in various cardiac pathologies. In the future, it will contribute to the development of effective diagnostic, preventive and therapeutic measures.
- 27 December 2024
- Published by Ulyanovsk State University in Ulyanovsk Medico-biological Journal
- No. 4
ROLE OF DOPAMINE IN THE REGULATION OF CARDIOVASCULAR SYSTEM
Dopamine is an endogenous catecholamine and its effects are not limited to the central nervous system. Thus, dopamine affects the gastrointestinal motility, hormone release, and sodium balance. Recently, the role of peripheral dopamine in regulating cardiac functions has been studied by various scientists. The aim of the review is to summarize the currently available data on the role of dopamine in cardiac regulation. Materials and Methods. Papers from PubMed, Google Scholar, and eLIBRARY.RU were analyzed for the literature review. Results. Dopamine, being an agonist of cardiac α- and β-adrenergic receptors, has positive chronotropic and inotropic cardiac effects. In proximal arteries, catecholamine causes dose-dependent contraction, whereas in distal arteries, low dopamine concentration leads to dilation, while high concentration causes contraction. Due to the wide variety of receptors, dopamine has a cardioprotective effect, reducing cardiac hypertrophy and fibrosis. Experimental studies with laboratory animals have shown that catecholamine suppresses inflammation mediated by NLRP3 inflammasome activation in cardiomyocytes, and reduces IL-6 and endothelin-1 release. Dopamine plays an important role in the pathogenesis of hypertension by regulating epithelial sodium transport and interacting with vasoactive hormones/humoral factors such as aldosterone, angiotensin, renin, and vasopressin. Dopamine may also have a negative cardiac effect. Use of a dopamine-adrenergic receptor agonist increases mortality risk among patients with advanced heart failure. High level of free catecholamine is an independent risk factor for future coronary events in patients with coronary heart disease. Conclusion. Dopamine plays a special role in cardiac regulation. However, further studies are desirable, as it is necessary to examine the changes in the catecholamine concentration in various cardiac pathologies. In the future, it will contribute to the development of effective diagnostic, preventive and therapeutic measures.
- Open Access
- 5 December 2023
- Published by ECO-Vector LLC in Kazan medical journal
- Vol. 104 (6) , 843-850
Serotonin and 5-hydroxyindoleacetic acid are involved in the pathogenesis of COVID-19 in children
Background. The new coronavirus infection COVID-19 is a pressing health problem around the world. This disease affects the respiratory, cardiovascular and other systems. The role of serotonin as one of the key factors in COVID-19 is discussed in the literature. Aim. Determination of the concentration of serotonin and its metabolite 5-hydroxyindoleacetic acid in the blood serum of children in the acute period of COVID-19 for use as a diagnostic criterion for the severity of the disease. Material and methods. A study that included 141 children aged 0 to 17 years was conducted: 92 patients hospitalized in a hospital with a diagnosis of COVID-19 without concomitant pathology made up the study group, 49 healthy children were included in the control group. The subjects were divided into two age groups: younger (0–2 years) and older (3–17 years). The groups of patients and children from the control group were comparable in age and gender. A study of the concentration of serotonin and its metabolite — 5-hydroxyindoleacetic acid — in the blood was carried out using high-performance liquid chromatography, and the results of laboratory and instrumental research methods (obtained from medical records) were evaluated. Based on the results of computed tomography, the proportion of involvement of the lung parenchyma in the pathological process was calculated: CT0 — absence of lung damage; CT1 — less than 25%; CT2 — 25–49%; CT3 — 50–74%; CT4 — more than 75%. Quantitative data were described using median (Me) and lower and upper quartiles (Q1–Q3). To analyze the data, the Pearson χ2 test, nonparametric Kruskal–Wallis and Mann–Whitney tests, as well as the ROC curve method were used. A correlation analysis was carried out using the Spearman coefficient and an assessment of the dependence of a quantitative variable on factors using the linear regression method. Results. In children with COVID-19 aged 0–2 years, the concentration of serotonin (969.41 pmol/ml) in the blood serum was statistically significantly higher by 49.1 times, in the group of 3–17 years (637.87 pmol/ml) — by 24.5 times compared to age-matched controls (19.74 pmol/ml; p 0.001 and 26.0 pmol/ml; p 0.001, respectively). The concentration of 5-hydroxyindoleacetic acid in patients 0–2 years old (204.90 pmol/ml) was 4.7 times higher relative to healthy children (43.56 pmol/ml; p=0.003), and in the older age group (78.25 pmol/ml) — 2.4 times higher (32.65 pmol/ml; p=0.012), which suggests increased breakdown of serotonin under the influence of monoamine oxidase A. Maximum concentrations of serotonin in blood serum were detected in children aged 0–2 years (1808.79 pmol/ml) with damage to the lung parenchyma from 50 to 74% (grade 3 according to computed tomography). However, in children aged 3–17 years, the maximum concentrations of serotonin (2036.95 pmol/ml) were detected with lung damage ranging from 25 to 49% (grade 2 according to computed tomography). In patients with COVID-19, when the concentration of serotonin in the blood was above 1046.5 pmol/ml, grade 2–4 lung lesions were predicted according to computed tomography, sensitivity 62.5%, specificity 75%. Conclusion. With COVID-19, a significant increase in the concentration of serotonin and 5-hydroxyindoleacetic acid in the blood was detected in children.
- 5 December 2023
- Published by ECO-Vector LLC in Kazan medical journal
- Vol. 104 (6) , 843-850
Open AccessSerotonin and 5-hydroxyindoleacetic acid are involved in the pathogenesis of COVID-19 in children
Background. The new coronavirus infection COVID-19 is a pressing health problem around the world. This disease affects the respiratory, cardiovascular and other systems. The role of serotonin as one of the key factors in COVID-19 is discussed in the literature. Aim. Determination of the concentration of serotonin and its metabolite 5-hydroxyindoleacetic acid in the blood serum of children in the acute period of COVID-19 for use as a diagnostic criterion for the severity of the disease. Material and methods. A study that included 141 children aged 0 to 17 years was conducted: 92 patients hospitalized in a hospital with a diagnosis of COVID-19 without concomitant pathology made up the study group, 49 healthy children were included in the control group. The subjects were divided into two age groups: younger (0–2 years) and older (3–17 years). The groups of patients and children from the control group were comparable in age and gender. A study of the concentration of serotonin and its metabolite — 5-hydroxyindoleacetic acid — in the blood was carried out using high-performance liquid chromatography, and the results of laboratory and instrumental research methods (obtained from medical records) were evaluated. Based on the results of computed tomography, the proportion of involvement of the lung parenchyma in the pathological process was calculated: CT0 — absence of lung damage; CT1 — less than 25%; CT2 — 25–49%; CT3 — 50–74%; CT4 — more than 75%. Quantitative data were described using median (Me) and lower and upper quartiles (Q1–Q3). To analyze the data, the Pearson χ2 test, nonparametric Kruskal–Wallis and Mann–Whitney tests, as well as the ROC curve method were used. A correlation analysis was carried out using the Spearman coefficient and an assessment of the dependence of a quantitative variable on factors using the linear regression method. Results. In children with COVID-19 aged 0–2 years, the concentration of serotonin (969.41 pmol/ml) in the blood serum was statistically significantly higher by 49.1 times, in the group of 3–17 years (637.87 pmol/ml) — by 24.5 times compared to age-matched controls (19.74 pmol/ml; p 0.001 and 26.0 pmol/ml; p 0.001, respectively). The concentration of 5-hydroxyindoleacetic acid in patients 0–2 years old (204.90 pmol/ml) was 4.7 times higher relative to healthy children (43.56 pmol/ml; p=0.003), and in the older age group (78.25 pmol/ml) — 2.4 times higher (32.65 pmol/ml; p=0.012), which suggests increased breakdown of serotonin under the influence of monoamine oxidase A. Maximum concentrations of serotonin in blood serum were detected in children aged 0–2 years (1808.79 pmol/ml) with damage to the lung parenchyma from 50 to 74% (grade 3 according to computed tomography). However, in children aged 3–17 years, the maximum concentrations of serotonin (2036.95 pmol/ml) were detected with lung damage ranging from 25 to 49% (grade 2 according to computed tomography). In patients with COVID-19, when the concentration of serotonin in the blood was above 1046.5 pmol/ml, grade 2–4 lung lesions were predicted according to computed tomography, sensitivity 62.5%, specificity 75%. Conclusion. With COVID-19, a significant increase in the concentration of serotonin and 5-hydroxyindoleacetic acid in the blood was detected in children.
- 20 November 2022
- Published by The National Academy of Pediatric Science and Innovation in Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics)
- Vol. 67 (5) , 163-169
Blood serotonin concentration in children with COVID-19
COVID-19 has a risk of thrombotic complications. Serotonin plays an important role in pathogenesis of thrombosis.Purpose. To evaluate level of serotonin and its metabolite in the blood of children with COVID-19.Methods. This study included 72 children aged 3 to 17 years. Of these, 43 patients (mean age 11.2 ± 4.8 years) diagnosed with COVID-19 without comorbidities made up the study group, 29 healthy children (mean age 11.8 ± 3.8 years) — the control group. Concentration of serotonin and its metabolite (5-HIAA) in the blood was determined using high performance liquid chromatography with electrochemical detection. Computed tomography data were used to determine severity of lung damage.Results. In our study children with COVID-19 aged 3 to 17 years had significantly higher serotonin and its metabolite levels compared to the control group. Concentration of serotonin in plasma in main group was 20–30 times higher than in the same-age control. The 5-HIAA/serotonin ratio in children with COVID-19 is significantly lower than in the control group. Levels of serotonin and 5-HIAA in children with COVID-19 depending on the severity of CT-scan lung damage showed no significant differences.Conclusion. Serotonin and its metabolite levels in plasma of children with COVID-19 is significantly increased. It may be related to platelet hyperactivation in SARS-CoV-2 infection and increased risk of thrombosis, which requires further research.
- 20 November 2022
- Published by The National Academy of Pediatric Science and Innovation in Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics)
- Vol. 67 (5) , 163-169
Blood serotonin concentration in children with COVID-19
COVID-19 has a risk of thrombotic complications. Serotonin plays an important role in pathogenesis of thrombosis.Purpose. To evaluate level of serotonin and its metabolite in the blood of children with COVID-19.Methods. This study included 72 children aged 3 to 17 years. Of these, 43 patients (mean age 11.2 ± 4.8 years) diagnosed with COVID-19 without comorbidities made up the study group, 29 healthy children (mean age 11.8 ± 3.8 years) — the control group. Concentration of serotonin and its metabolite (5-HIAA) in the blood was determined using high performance liquid chromatography with electrochemical detection. Computed tomography data were used to determine severity of lung damage.Results. In our study children with COVID-19 aged 3 to 17 years had significantly higher serotonin and its metabolite levels compared to the control group. Concentration of serotonin in plasma in main group was 20–30 times higher than in the same-age control. The 5-HIAA/serotonin ratio in children with COVID-19 is significantly lower than in the control group. Levels of serotonin and 5-HIAA in children with COVID-19 depending on the severity of CT-scan lung damage showed no significant differences.Conclusion. Serotonin and its metabolite levels in plasma of children with COVID-19 is significantly increased. It may be related to platelet hyperactivation in SARS-CoV-2 infection and increased risk of thrombosis, which requires further research.
- Open Access
- 9 December 2021
- Published by The National Academy of Pediatric Science and Innovation in Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics)
- Vol. 66 (5) , 88-96
Clinical manifestations of new coronavirus infection (COVID-19) in children admitted to hospital
Objective. To describe clinical and laboratory features of COVID-19 in children admitted to the hospital.Children characteristics and research methods. The authors carried out a retrospective observational study, which included 204 children admitted to the Kazan hospital with a diagnosis of “new coronavirus infection” in the period from May 1 to October 30, 2020.Results. It was revealed that all hospitalized children had RNA of the SARS-CoV-2 virus (100%) in a smear from the nasopharynx and oropharynx detected by PCR and only 50% of patients were diagnosed with lung tissue lesions by computed tomography. The clinical picture of COVID-19 in children most often corresponds to the classic manifestations of a respiratory viral infection. Risk factors for the development of severe forms, described in adults, were recorded only in isolated cases in our study.Conclusion. The clinical picture of COVID-19 in children most often corresponds to the classic manifestations of a respiratory viral infection. Risk factors for the development of severe forms, described in adults, were recorded in isolated cases in our study.
- 9 December 2021
- Published by The National Academy of Pediatric Science and Innovation in Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics)
- Vol. 66 (5) , 88-96
Open AccessClinical manifestations of new coronavirus infection (COVID-19) in children admitted to hospital
Objective. To describe clinical and laboratory features of COVID-19 in children admitted to the hospital.Children characteristics and research methods. The authors carried out a retrospective observational study, which included 204 children admitted to the Kazan hospital with a diagnosis of “new coronavirus infection” in the period from May 1 to October 30, 2020.Results. It was revealed that all hospitalized children had RNA of the SARS-CoV-2 virus (100%) in a smear from the nasopharynx and oropharynx detected by PCR and only 50% of patients were diagnosed with lung tissue lesions by computed tomography. The clinical picture of COVID-19 in children most often corresponds to the classic manifestations of a respiratory viral infection. Risk factors for the development of severe forms, described in adults, were recorded only in isolated cases in our study.Conclusion. The clinical picture of COVID-19 in children most often corresponds to the classic manifestations of a respiratory viral infection. Risk factors for the development of severe forms, described in adults, were recorded in isolated cases in our study.
- Open Access
- 10 August 2020
- Published by Paediatrician Publishers LLC in Current Pediatrics
- Vol. 19 (3) , 214-219
Evolution of Mixed Connective Tissue Disease in 7 Years Old Child: Clinical Case
Background. Mixed connective tissue disease (Sharp syndrome) is the rare chronic autoimmune pathology combining various features of systemic lupus erythematosus, systemic scleroderma, rheumatoid arthritis, dermatomyositis and high antibody titer to nuclear ribonucleoprotein. The mixed connective tissue disease may evolve into other systemic diseases over time. Description of any cases of mixed connective tissue disease and its evolution in Russian patients has not been published previously.Clinical Case Description. The results of observations of the child with clinical and immunological signs of the mixed connective tissue disease followed by the progression of systemic scleroderma symptoms and development of Sjogren's syndrome in the short period of time are presented in the article. Improvement (such as pain attenuation, increase in volume of movements in affected joints, decrease of Raynaud syndrome manifestations duration) was observed on treatment (methotrexate 10 mg/week with subsequent addition of prednisolone 0.75 mg/kg/day).Conclusion. Timely diagnostics of clinical signs of the systemic diseases debut is crucial for correct patient routing and for achieving of disease improvement.
- 10 August 2020
- Published by Paediatrician Publishers LLC in Current Pediatrics
- Vol. 19 (3) , 214-219
Open AccessEvolution of Mixed Connective Tissue Disease in 7 Years Old Child: Clinical Case
Background. Mixed connective tissue disease (Sharp syndrome) is the rare chronic autoimmune pathology combining various features of systemic lupus erythematosus, systemic scleroderma, rheumatoid arthritis, dermatomyositis and high antibody titer to nuclear ribonucleoprotein. The mixed connective tissue disease may evolve into other systemic diseases over time. Description of any cases of mixed connective tissue disease and its evolution in Russian patients has not been published previously.Clinical Case Description. The results of observations of the child with clinical and immunological signs of the mixed connective tissue disease followed by the progression of systemic scleroderma symptoms and development of Sjogren's syndrome in the short period of time are presented in the article. Improvement (such as pain attenuation, increase in volume of movements in affected joints, decrease of Raynaud syndrome manifestations duration) was observed on treatment (methotrexate 10 mg/week with subsequent addition of prednisolone 0.75 mg/kg/day).Conclusion. Timely diagnostics of clinical signs of the systemic diseases debut is crucial for correct patient routing and for achieving of disease improvement.